MOTS-c Dosage: What the Research Reports

What is MOTS-c, and why is its dosing uncertain?

MOTS-c is a short peptide encoded inside mitochondrial DNA that Lee et al. (2015) showed activates AMPK and improves metabolic measures in mice, but because no human dosing trial has been completed, no established human dose exists.

MOTS-c stands for a 16 amino acid peptide read from the mitochondrial 12S rRNA region. Lee et al. (2015, Cell Metabolism) reported that it works through AMPK, a cellular energy sensor, and that treated mice showed better insulin sensitivity and resistance to diet-induced obesity. Those findings describe an effect in animals, not a demonstrated outcome or a treatment in people. The uncertainty in dosing follows directly from that: the quantitative dose data come from rodents, and rodent doses are set by body weight and route in ways that do not carry over to human use.

What dose of MOTS-c did the research actually use?

The most-cited data come from Lee et al. (2015), where mice received MOTS-c by intraperitoneal injection, meaning injection into the abdominal cavity, dosed per kilogram of body weight rather than as a fixed milligram amount for people.

The figures below reflect what the foundational mouse study reported; no human protocol has been established. This is educational, not a prescription or a personal recommendation.

Read the table as research context, not as a plan. A body-weight dose in a 25 gram mouse is not a milligram number a person can copy, and the route used in the study is a laboratory route, not a consumer one. The figures exist to describe the experiment, and they only describe animals.

Can mouse mg per kg doses be converted to a human dose?

Not reliably: animal-to-human scaling is a rough estimation tool for designing early trials, not a personal dose, and it has never been validated for MOTS-c because no human trial has been completed.

Researchers sometimes estimate a human-equivalent starting dose from animal data using body surface area scaling. That method is built to help design a first human study, and it produces a planning estimate, not a proven dose. For MOTS-c there is no completed human trial to confirm any converted number, so treating a scaled figure as a dose would be guessing. This is the core reason the site does not publish a MOTS-c dose: the honest answer is that the human number is not known.

Is there any human data on MOTS-c dosing?

No completed human dosing trial for MOTS-c has been published, so human dose, frequency, half-life, and safety thresholds are all unestablished, and the evidence rests on animal work such as Lee et al. (2015).

It helps to compare this with peptides that do have a human dosing base. GLP-1 class peptides went through large human dose-finding trials, for example Wilding et al. (2021, New England Journal of Medicine) for semaglutide and Jastreboff et al. (2022, New England Journal of Medicine) for tirzepatide. Those trials tested defined doses in thousands of people and reported outcomes. MOTS-c has nothing of that kind. That gap is not a detail; it is the difference between a compound with a human dosing record and one without. MOTS-c is offered as a research material, and there is no approved human therapeutic use.

How does mg to unit math work for a reconstituted peptide? (reference only)

This is arithmetic, not a dose recommendation: once a lyophilized peptide is reconstituted, concentration equals milligrams of peptide divided by milliliters of liquid, and insulin-syringe "units" are simply a volume marking, where 100 units equals 1 mL on a standard U-100 syringe. To run this same arithmetic for any vial without working it out by hand, use the peptide reconstitution calculator.

Because 100 units equals 1 mL, one unit equals 0.01 mL, so what a single unit contains depends only on the concentration. The table below shows how much peptide sits in one unit at a few example concentrations. It does not convert any target amount into a draw, because MOTS-c has no established human dose to convert.

This is reference arithmetic about concentration only. Each row shows what one syringe unit contains at that concentration. It is not a dose, not a recommendation, and not injection instructions, and no target amount for a person is shown. What a given individual should do, if anything, is a decision for a qualified clinician.

What safety signals appear in MOTS-c research?

Published MOTS-c safety information is limited to animal studies, so human tolerability, side effects, and long-term safety are not established in the literature.

Lee et al. (2015) reported metabolic changes in mice, such as improved insulin sensitivity and reduced diet-induced obesity, but those are efficacy observations in animals, not a human safety profile. Human pharmacokinetics, including half-life and clearance, are not characterized in published human trials. Absence of reported harm in a mouse study is not evidence of human safety, and the correct summary is that the human safety picture is unknown.

What are the reported benefits of MOTS-c?

The reported benefits are animal findings, not proven human outcomes: in mice, Lee et al. (2015) reported that MOTS-c activated AMPK, improved insulin sensitivity, and increased resistance to diet-induced obesity.

Those three results, AMPK activation, better insulin sensitivity, and resistance to diet-induced obesity, are the effects most often listed as MOTS-c benefits. Read them precisely: they were measured in mice in a single foundational study, they describe a metabolic effect in animals, and they have not been confirmed as benefits in people, because no completed human trial has tested them. The honest framing is that these are promising preclinical observations, not established human benefits.

Is there a MOTS-c dosing protocol?

There is no established human MOTS-c dosing protocol. A protocol would require a completed human trial defining dose, frequency, route, and duration, and none has been published.

What circulates online as a protocol is not drawn from a human study, because the only quantitative dose data are the mouse milligram-per-kilogram figures reported by Lee et al. (2015), given by intraperitoneal injection. Those figures describe an experiment in animals; they do not define a schedule for a person. Any protocol for a specific individual is a clinical decision, not something this educational page sets.

Is there a MOTS-c dosage chart?

There is no validated human MOTS-c dosage chart. The only quantitative figures available are the mouse milligram-per-kilogram data shown in the research table above (Lee et al., 2015), which describe an animal experiment, not a human schedule.

A real dosage chart would list human doses by goal or body weight, and that requires completed human dosing trials, which MOTS-c does not have. Charts presented elsewhere as human MOTS-c dosing are not backed by a published human trial. The reference table earlier on this page is the honest version of the data: it reports what the mouse study used and marks the human row as not established.

Related reading

To go deeper, see the main MOTS-c overview and the companion page on MOTS-c side effects. For background on how peptides work as a class, read what are peptides. For the contrast used above between a compound with a human dosing record and one without, see GLP-1 receptor agonists explained.